Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial

Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial

The tetravalent dengue vaccine (CYD-TDV) is approved for use as a 3-dose series for the prevention of dengue in seropositive individuals ≥9 years. A randomized, placebo-controlled, phase II study of a booster dose of CYD-TDV in individuals who completed the 3-dose schedule >5 years previously (NC...

Full description

Bibliographic Details
Main Authors: Juliana Park, Sophia Archuleta, May-Lin Helen Oh, Lynette Pei-Chi Shek, Hao Wang, Matthew Bonaparte, Carina Frago, Alain Bouckenooghe, Frederique Jantet-Blaudez, Sarah Begue, Sophie Gimenez-Fourage, Anke Pagnon
Format: Article
Language:English
Published: Taylor & Francis Group 2021-07-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
cyd-tdv
dengue vaccine
b-cell response
t-cell response
booster vaccine
long-term follow-up
Online Access:http://dx.doi.org/10.1080/21645515.2020.1861875

Internet

http://dx.doi.org/10.1080/21645515.2020.1861875

Similar Items